Рет қаралды 803
OncLive
Joyce A. O’Shaughnessy, MD, and Aditya Bardia, MD, MPH, outline the potential for use of antibody-drug conjugates, including sacituzumab and glembatumumab, for treating triple-negative breast cancer.